This ends a drawn out legal battle brought by Genevant and Arbutus against Moderna under a week before the jury trial was set ...

Lantern announced partnerships with Novant Health and EmergeOrtho as part of its ongoing collaboration with the North Carolina State Health Plan. Nanox is collaborating with three new partners to ...

The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud. | Moderna will pay $950 ...

In a conversation with Pharmaceutical Executive Ron Lanton, Senior Partner & Global Strategist, Lanton, Lanton & Sosa Law ...

During this latest round of earnings calls, marketing didn’t factor heavily in these discussions. Lilly did address sharply rising commercial costs which go in tandem with its massive revenue growth, ...

Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If ...

By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the ...

Roivant announced that its subsidiary Genevant Sciences and Arbutus Biopharma have entered into a $2.25 billion global settlement with Moderna to resolve all US and international enforcement actions ...

Arbutus and Genevant's complaint claimed that Moderna's mRNA-based Spikevax shot used lipid nanoparticle (LNP) delivery ...

While the FDA has flip-flopped on whether to review Moderna’s combination influenza and COVID-19 vaccine, it’s full speed ...

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable ...